AnaptysBio (ANAB)

• Market cap: $1.06B
• 1 day: 6.11%
• 5 days: 4.95%
• 1 month: 26.28%
• 3 months: 69.48%
• 6 months: 89.86%
• Year to date: 185.93%
• 1 year: 71.99%
• 5 years: 32.18%
• 10 years: 124.71%
• Sector: Healthcare
• Industry: Biotechnology

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136